Literature DB >> 10160484

Weekly monitoring of influenza impact in Belgium (1993-1995).

R Snacken1.   

Abstract

The primary objectives of an influenza monitoring programme are early detection of an epidemic and the identification of the viruses responsible. The healthcare impact of the disease is often some time after the epidemic. In Belgium data on the consequences of influenza are recorded weekly, which provides an early estimate of the severity of the epidemic. Data collected during 3 influenza seasons (1993-95) showed that during the peak of the very moderate influenza A/H3N2 outbreak in 1993-94, general practitioner consultations for acute respiratory infections increased by 100%, work absenteeism by 56%, total sales of pharmaceuticals by pharmacists by 26% and overall mortality by 14%. From these data, we estimated that 498,400 working days were lost during the peak week in Belgium in 1993, and 848 excess deaths were observed during the whole of the 1993-94 epidemic. 12% of those who died were aged less than 60 years. Hospitalisation data must be included in the future in order to complete the information that is essential for formulating public health policies on influenza vaccination.

Entities:  

Mesh:

Year:  1996        PMID: 10160484     DOI: 10.2165/00019053-199600093-00009

Source DB:  PubMed          Journal:  Pharmacoeconomics        ISSN: 1170-7690            Impact factor:   4.981


  9 in total

1.  Five years of sentinel surveillance of acute respiratory infections (1985-1990): the benefits of an influenza early warning system.

Authors:  R Snacken; J Lion; V Van Casteren; R Cornelis; F Yane; M Mombaerts; W Aelvoet; A Stroobant
Journal:  Eur J Epidemiol       Date:  1992-07       Impact factor: 8.082

2.  Review of cost-benefit analyses of influenza vaccine.

Authors:  J Perez-Tirse; P A Gross
Journal:  Pharmacoeconomics       Date:  1992-09       Impact factor: 4.981

3.  [Cost-effectiveness analysis of antigrippal vaccination in a rural population (La Victoria, Cordoba)].

Authors:  F J Gavira; R Lardinois
Journal:  Med Clin (Barc)       Date:  1990-05-26       Impact factor: 1.725

4.  Methods for current statistical analysis of excess pneumonia-influenza deaths.

Authors:  Robert E Serfling
Journal:  Public Health Rep       Date:  1963-06       Impact factor: 2.792

5.  Influenza-related excess mortality in The Netherlands 1989/90.

Authors:  M J Sprenger; R J Diepersloot; W E Beyer; N Masurel
Journal:  Lancet       Date:  1990-08-11       Impact factor: 79.321

6.  Economic impact of influenza. The individual's perspective.

Authors:  S C Schoenbaum
Journal:  Am J Med       Date:  1987-06-19       Impact factor: 4.965

7.  Influenza: quantifying morbidity and mortality.

Authors:  A S Monto
Journal:  Am J Med       Date:  1987-06-19       Impact factor: 4.965

8.  Sickness absence at the French National Electric and Gas Company.

Authors:  A Chevalier; D Luce; C Blanc; M Goldberg
Journal:  Br J Ind Med       Date:  1987-02

9.  Excess deaths attributable to influenza in England and Wales: age at death and certified cause.

Authors:  H E Tillett; J W Smith; C D Gooch
Journal:  Int J Epidemiol       Date:  1983-09       Impact factor: 7.196

  9 in total
  3 in total

1.  Survey on influenza laboratory diagnostic and surveillance methods in Europe. European Scientific Working Group on Influenza.

Authors:  C Hannoun; B Tumova
Journal:  Eur J Epidemiol       Date:  2000-03       Impact factor: 8.082

2.  Influenza surveillance in Europe: establishing epidemic thresholds by the moving epidemic method.

Authors:  Tomás Vega; Jose Eugenio Lozano; Tamara Meerhoff; René Snacken; Joshua Mott; Raul Ortiz de Lejarazu; Baltazar Nunes
Journal:  Influenza Other Respir Viruses       Date:  2012-08-16       Impact factor: 4.380

3.  Influenza epidemics in the United States, France, and Australia, 1972-1997.

Authors:  Cécile Viboud; Pierre-Yves Boëlle; Khashayar Pakdaman; Fabrice Carrat; Alain-Jacques Valleron; Antoine Flahault
Journal:  Emerg Infect Dis       Date:  2004-01       Impact factor: 6.883

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.